


## PHARMACEUTICAL 2019

## MANNKIND CORP Rank 246 of 371





## PHARMACEUTICAL 2019

## MANNKIND CORP Rank 246 of 371

The relative strengths and weaknesses of MANNKIND CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MANNKIND CORP compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 101% points. The greatest weakness of MANNKIND CORP is the variable Assets, Current, reducing the Economic Capital Ratio by 76% points.

The company's Economic Capital Ratio, given in the ranking table, is -279%, being 52% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	81,854
Cost of Goods Sold	19,402
Intangible Assets	0
Liabilities, Current	75,241
Liabilities, Non-Current	10,680
Other Assets	249
Other Compr. Net Income	-1.0
Other Expenses	-3,161
Other Liabilities	196,866
Other Net Income	-10,140
Property and Equipment	25,602
Research and Development	8,737
Revenues	27,859
Selling, General and Administrative Expense	79,716

Output Variable	Value in 1000 USD
Assets	107,705
Liabilities	282,787
Expenses	104,694
Stockholders Equity	-175,082
Net Income	-86,975
Comprehensive Net Income	-86,976
Economic Capital Ratio	-279%